In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Synlogic gets $40mm via Series B

Executive Summary

Synlogic Inc. (creating therapeutics based on its synthetic biology and microbiome platforms) raised $40mm in its Series B financing led by OrbiMed HealthCare Fund Management, which adds a board member and was joined by other new backer Deerfield Management and returning shareholders Atlas Venture and New Enterprise Associates. Proceeds will help support development of its urea cycle disorder and phenylketonuria programs, which are expected to enter the clinic in 2017. The financing comes just one week after Synlogic teamed up with AbbVie, the biotech's first corporate partner.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies